Browse > Article
http://dx.doi.org/10.4046/trd.2012.72.3.323

A Case of Balsalazide-Induced Limited Form of Granulomatosis with Polyangiitis with Bronchiolitis Obliterans Organizing Pneumonia-like Variant in Ulcerative Colitis  

Kang, Shin-Myung (Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital)
Jang, Young-Rock (Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital)
Yoon, Hyun-Hwa (Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital)
Kim, Su-Ji (Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital)
Kim, Eun-Young (Department of Radiology, Gachon University Gil Hospital)
Ha, Seung-Yeon (Department of Pathology, Gachon University Gil Hospital)
Park, Jeong-Woong (Department of Pulmonary and Critical Care Medicine, Gachon University Gil Hospital)
Publication Information
Tuberculosis and Respiratory Diseases / v.72, no.3, 2012 , pp. 323-327 More about this Journal
Abstract
5-Aminosalicylate agents are the main therapeutic agents for ulcerative colitis. Balsalazide is a prodrug of 5-aminosalicylate and has fewer side effects than the other 5-aminosalicylate agents. Pulmonary complications resembling granulomatosis with polyangiitis in ulcerative colitis are extremely rare. Here, we report a patient with ulcerative colitis on balsalazide presenting respiratory symptoms and multiple pulmonary nodules from a chest radiography that was pathologically diagnosed with a limited form of granulomatosis with polyangiitis with bronchiolitis obliterans organizing pneumonia-like variant. To our knowledge, this is the first report of a balsalazide-induced limited form of granulomatosis with polyangiitis with bronchiolitis obliterans organizing pneumonia-like variant.
Keywords
Balsalazide; Wegener Granulomatosis; Colitis, Ulcerative;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Muzzi A, Ciani F, Bianchini D, Festini G, Volpe C. Adverse pulmonary effects of mesalamine. Chest 1995; 108:1181.
2 Park JE, Hwangbo Y, Chang R, Chang YW, Jang JY, Kim BH, et al. Mesalazine-induced eosinophilic pneumonia in a patient with Crohn's disease. Korean J Gastroenterol 2009;53:116-20.
3 Tanigawa K, Sugiyama K, Matsuyama H, Nakao H, Kohno K, Komuro Y, et al. Mesalazine-induced eosinophilic pneumonia. Respiration 1999;66:69-72.
4 Bitton A, Peppercorn MA, Hanrahan JP, Upton MP. Mesalamine-induced lung toxicity. Am J Gastroenterol 1996;91:1039-40.
5 Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine- related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm Bowel Dis 2003;9: 308-15.
6 Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 1993;72:151-83.
7 Yano S, Kobayashi K, Kato K, Nishimura K. A limited form of Wegener's granulomatosis with bronchiolitis obliterans organizing pneumonitis-like variant in an ulcerative colitis patient. Intern Med 2002;41:1013-5.
8 Kasuga A, Mandai Y, Katsuno T, Sato T, Yamaguchi T, Yokosuka O. Pulmonary complications resembling Wegener's granulomatosis in ulcerative colitis with elevated proteinase-3 anti-neutrophil cytoplasmic antibody. Intern Med 2008;47:1211-4.
9 Salerno SM, Ormseth EJ, Roth BJ, Meyer CA, Christensen ED, Dillard TA. Sulfasalazine pulmonary toxicity in ulcerative colitis mimicking clinical features of Wegener's granulomatosis. Chest 1996;110:556-9.
10 Stebbing J, Askin F, Fishman E, Stone J. Pulmonary manifestations of ulcerative colitis mimicking Wegener's granulomatosis. J Rheumatol 1999;26:1617-21.
11 Meyer KC, Raghu G. Bronchoalveolar lavage for the evaluation of interstitial lung disease: is it clinically useful? Eur Respir J 2011;38:761-9.
12 Wiggins JB, Rajapakse R. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol 2009;5:1279-84.
13 Tursi A. Balsalazide in treating colonic diseases. Expert Opin Drug Metab Toxicol 2009;5:1555-63.
14 Khan A, Lawson CA, Quinn MA, Isdale AH, Green MJ. Successful treatment of ANCA-negative Wegener's granulomatosis with rituximab. Int J Rheumatol 2010; 2010:846063.